Psychiatric Disorders

REL-1017 is an investigational oral, novel N-methyl-D-aspartate receptor channel blocker.

Likelihood of experiencing a serious medical outcome or being admitted to a health care facility was increased for children younger than 6 years.

Findings seen in real-world patients with a range of chronic health conditions.

Findings seen for transgender and gender-diverse individuals desiring testosterone therapy.

Among patients with ADRD receiving care from a home health agency, antipsychotic use was tied to less improvement in activities of daily living.

Pitolisant is a selective histamine-3 receptor antagonist/inverse agonist.

Comparable rates of in-hospital adverse events seen among seniors prescribed oral antipsychotics after major surgery

Significant benefit seen as early as 8 days compared with placebo.

Selective serotonin reuptake inhibitor treatment tied to lower risk for maternal mental health problems and child externalizing behaviors across early childhood.

A 12-week app-based exercise program may reduce depressive symptoms in health care professionals, but adherence to the program may be an obstacle.

Lisdexamfetamine dimesylate capsules and chewable tablets are indicated for ADHD in patients aged 6 years and older, and for moderate to severe binge-eating disorder in adults.

Recommendations include increase in research funding to screen and identify those at risk, connect with resources

Benzodiazepines, anxiety disorders linked to dementia risk, but no additional risk seen for benzodiazepines in patients with anxiety disorders.

Oral postpartum depression treatment approved; generic naloxone nasal spray now available; weight management drug shows promise in reducing major cardiovascular events; CDC recommends routine use of RSV vaccine; social anxiety disorder spray shows potential.

Authors dub the term benzodiazepine-induced neurological dysfunction to describe neurological complications.

Fasedienol is a first-in-class, rapid-onset investigational pherine nasal spray.

Zurzuvae is expected to become available in the fourth quarter of 2023 following scheduling as a controlled substance by the DEA.

Gender differences seen in prevalence, timing, and most common mental disorders.